Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164741 | 0.96 | — | — | |
| Bromide SCHEMBL11876634 | 0.92 | — | — | |
| Iodide SCHEMBL35210416 | 0.92 | — | — | |
| Ammonia Solution, Strong SCHEMBL15255061 | 0.92 | — | — | |
| Alcohol SCHEMBL28115069 | 0.83 | — | — | |
| Ether SCHEMBL7147588 | 0.78 | TSHR (0.33) | — | |
| Oxalic Acid SCHEMBL28088338 | 0.78 | RNPEP (0.39) | — | |
| SCHEMBL1473251 | 0.76 | — | — | |
| SCHEMBL10894495 | 0.74 | TSHR (0.30) | — | |
| SCHEMBL22662 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108949-A | Method for preparing 2- (methylsulfonyl) ethylamine hydrochloride by using methyl mercaptan | 江苏恒沛药物科技有限公司 | 2022-09-27 | — | — | CN | claimed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| CN-120322093-A | Carbon-based organic-inorganic perovskite solar cell based on modification of 2-methylthio-1-ethylamine hydrochloride | 河北工业大学 | 2025-07-15 | — | — | CN | disclosed |
| CN-120322093-A | Carbon-based organic-inorganic perovskite solar cell based on modification of 2-methylthio-1-ethylamine hydrochloride | 河北工业大学 | 2025-07-15 | — | — | CN | disclosed |
| CN-119371419-A | PKMYT1 kinase inhibitors | 杭州邦顺制药有限公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| CN-116410132-B | 8-Hydroxyquinoline compound, preparation method thereof and application thereof in preparation of antitumor drugs | 广东工业大学 | 2024-07-09 | — | — | CN | disclosed |
| CN-109897011-B | IDO inhibitor and application thereof | 上海华汇拓医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| CN-116410132-A | 8-hydroxyquinoline compound, preparation method thereof and application thereof in preparation of antitumor drugs | 广东工业大学 | 2023-07-11 | — | — | CN | disclosed |
| US-8916574-B2 | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors | QILU PHARMACEUTICAL CO., LTD. (CN) | 2014-12-23 | — | — | US | disclosed |
| US-20130289029-A1 | Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist | NOVO NORDISK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| EP-2607363-A1 | FUSED RING COMPOUND FOR USE AS MINERALOCORTICOID RECEPTOR ANTAGONIST | KBP Biosciences Co., Ltd. (CN) | 2013-06-26 | — | — | EP | disclosed |
| US-20120208833-A1 | 4-(Substituted Anilino)-Quinazoline Derivatives Useful as Tyrosine Kinase Inhibitors | QILU PHARMACEUTICAL CO., LTD. (CN) | 2012-08-16 | — | — | US | disclosed |
| EP-2484678-A1 | 4-(SUBSTITUTED ANILINO)QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Qilu Pharmaceutical Co., Ltd (CN) | 2012-08-08 | — | — | EP | disclosed |
| EP-1906242-A1 | PHOTOSENSITIVE RESIN COMPOSITION | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2008-04-02 | — | — | EP | disclosed |
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |